By identifying ER stress as a key modulator of VEGF expression in monocytes, our study suggests that targeting ER stress or its downstream ROS production may represent a therapeutic strategy to attenuate pathological angiogenesis and inflammation in obesity-related cardiometabolic diseases. This evidence concerns the gene VEGFA and obesity disorder.